In Taiwan, multinational drug manufacturers and the largerdomestically-owned research-based companies expect that their profits will grow about 10% this year, as a result of the introduction by the Department of Health of a new system separating doctors' drug prescribing and dispensing activities.
The government is actively promoting the change, which industry observers say will be harmful for the medium-sized and smaller local companies.
The China Post reports that most of the larger locally-owned companies are gearing up for the change by expanding their over-the-counter medicine businesses, either through establishing their own pharmacy chains or strengthening existing links with pharmacies. Other strategies being employed by these companies are increasing their production of health foods and organic foods, and expanding the operations of their subsidiaries in mainland China.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze